Inflammatory Bowel Disease and Thrombosis

被引:6
作者
Tezel, Ahmet [1 ]
Demir, Muzaffer [2 ]
机构
[1] Trakya Univ, Dept Gastroenterol, Sch Med, Tip Fak, TR-22030 Edirne, Turkey
[2] Trakya Univ, Dept Hematol, Sch Med, TR-22030 Edirne, Turkey
关键词
Inflammatory bowel disease; Thrombosis; V-LEIDEN MUTATION; MOLECULAR-WEIGHT HEPARIN; VENOUS THROMBOSIS; ULCERATIVE-COLITIS; VEIN-THROMBOSIS; RISK-FACTOR; THROMBOEMBOLISM; COAGULATION; PLACEBO; HOMOCYSTEINE;
D O I
10.5505/tjh.2012.04557
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Inflammatory Bowel Disease (IBD) is a group of chronic and relapsing inflammatory disorders of the gastrointestinal system. In these cases, findings are detected in extraintestinal systems also. There is a tendency for thrombotic events in IBD, as in the other inflammatory processes. The pathogenesis of this thrombotic tendency is multidimensional, including lack of natural anticoagulants, prothrombotic media induced via the inflammatory process, long-term sedentary life style, steroid use, surgery, and catheter placement. The aim of this review was to highlight the positive relationship between IBD and thrombotic events, and the proper treatment of at-risk patients.
引用
收藏
页码:111 / 119
页数:9
相关论文
共 58 条
[1]  
Akar N, 2009, TURK J HEMATOL, V26, P9
[2]   Extensive arterial and venous thrombosis complicating chronic ulcerative colitis [J].
Bargen, JA ;
Barker, NW .
ARCHIVES OF INTERNAL MEDICINE, 1936, 58 (01) :17-31
[3]  
Bernstein CN, 2001, THROMB HAEMOSTASIS, V85, P430
[4]   MUTATION IN BLOOD-COAGULATION FACTOR-V ASSOCIATED WITH RESISTANCE TO ACTIVATED PROTEIN-C [J].
BERTINA, RM ;
KOELEMAN, BPC ;
KOSTER, T ;
ROSENDAAL, FR ;
DIRVEN, RJ ;
DERONDE, H ;
VANDERVELDEN, PA ;
REITSMA, PH .
NATURE, 1994, 369 (6475) :64-67
[5]   Low molecular weight heparin (tinzaparin) vs. placebo in the treatment of mild to moderately active ulcerative colitis [J].
Bloom, S ;
Kiilerich, S ;
Lassen, MR ;
Forbes, A ;
Leiper, K ;
Langholz, E ;
Irvine, EJ ;
O'Morain, C ;
Lowson, D ;
Orm, S .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 19 (08) :871-878
[6]  
Botto LD, 2000, AM J EPIDEMIOL, V151, P862
[7]   Natural anticoagulant protein levels in Turkish patients with inflammatory bowel disease [J].
Cakal, Basak ;
Gokmen, Ayla ;
Yalinkilic, Mesut ;
Cakal, Erman ;
Ayaz, Selime ;
Nadir, Isilay ;
Ozin, Yasemin ;
Dagli, Ulku ;
Ulker, Aysel .
BLOOD COAGULATION & FIBRINOLYSIS, 2010, 21 (02) :118-121
[8]   Hemostatic abnormalities in inflammatory bowel disease [J].
Chiarantini, E ;
Valanzano, R ;
Liotta, AA ;
Cellai, AP ;
Fedi, S ;
Ilari, I ;
Prisco, D ;
Tonelli, F ;
Abbate, R .
THROMBOSIS RESEARCH, 1996, 82 (02) :137-146
[9]   Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial [J].
Cohen, AT ;
Davidson, BL ;
Gallus, AS ;
Lassen, MR ;
Prins, MH ;
Tomkowski, W ;
Turpie, AGG ;
Egberts, JFM ;
Lensing, AWA .
BMJ-BRITISH MEDICAL JOURNAL, 2006, 332 (7537) :325-327
[10]   Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients [J].
Cohen, AT ;
Alikhan, R ;
Arcelus, JI ;
Bergmann, JF ;
Haass, S ;
Merli, G ;
Spyropoulos, AC ;
Tapson, VF ;
Turpie, AGG .
THROMBOSIS AND HAEMOSTASIS, 2005, 94 (04) :750-759